Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Phase 3
Active, not recruiting
NCT02032823
| Condition | Breast Cancer |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | AstraZeneca |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 1,837 participants |
|---|
| Interventions | Olaparib |
|---|
| Start date | Apr 22, 2014 |
|---|
| Completion date | Mar 27, 2020 |
|---|
| Results posted | Dec 8, 2021 |
|---|
Summary
Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy
Invasive Disease Free Survival (IDFS)
From date of randomisation to data cut off: 27 March 2020 (approximately 5 years 11 months) · Participants
| Olaparib | 106 Participants |
|---|
| Placebo | 178 Participants |
|---|
| p-value | 0.0000073 |
|---|
| Hazard Ratio (HR) | 0.581 (95% CI 0.409–0.816) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.